Abeona Therapeutics
Commercializes ZEVASKYN for RDEB wounds through qualified treatment centers.
Something off on this page? Send us feedback.
Profile
Sells ZEVASKYN, an autologous cell-based gene therapy for RDEB wounds, through a qualified-treatment-center model. Operations are centered in Cleveland, where Abeona runs its own cGMP manufacturing facility and carries FDA-required long-term safety follow-up for treated patients.
Develops and sells ZEVASKYN, also known as prademagene zamikeracel, for wounds in adults and children with recessive dystrophic epidermolysis bullosa. The company reports a single segment and has added ABO-701 as an early pipeline asset after deprioritizing ophthalmology programs.
Commercial execution runs through qualified treatment centers and an internal Cleveland cGMP facility, the Elisa Linton Center. That setup gives the launch a narrow operating model: patient biopsy, manufacturing, and treatment-site readiness matter as much as conventional drug distribution.
Regulatory obligations remain part of the business model. FDA approval carries long-term postmarketing safety follow-up for treated patients, and current operations are shaped by ZEVASKYN commercialization rather than a broad mature portfolio.
Company facts
Key statistics
Year to date +11.7% · Average volume (30d) 1.4M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 14, 2026 | Industrial Alliance Securities | Target | $15 | ||
| Aug 14, 2026 | Oppenheimer | Reiterate | Outperform | $16 | $21 |
| Mar 17, 2026 | Stifel Nicolaus | Target | $20 | $17 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.23 | −$0.35 | −51.1% | $12.2M | $11.4M | −7.0% | −14.88% |
| May 13, 2026Q1 FY26 | −$0.33 | −$0.30 | +9.1% | $4.6M | $8.7M | +90.7% | −1.93% |
| Mar 17, 2026Q4 FY25 | −$0.35 | −$0.34 | +2.9% | $4.4M | $5.4M | +22.0% | −4.41% |
| Nov 12, 2025Q3 FY25 | −$0.27 | −$0.10 | +63.0% | $5.6M | — | — | −8.30% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $400.0K | $0 | $5.4M | $8.7M | $11.4M | |
| Gross profit | $0 | $300.0K | −$488.0K | $2.6M | $5.2M | $7.2M | |
| Operating income | −$19.7M | −$22.8M | −$24.0M | −$22.9M | −$23.0M | −$13.7M | |
| Net income | −$12.0M | $108.8M | −$5.2M | −$20.5M | −$17.1M | −$20.2M | |
| Diluted EPS | −$0.24 | $1.71 | −$0.10 | −$0.36 | −$0.30 | −$0.35 | |
| Gross margin | — | 75.0% | — | 47.7% | 59.1% | 63.3% | |
| Operating margin | — | -5,698.0% | — | -422.7% | -264.1% | -120.0% |
Fiscal years (4-quarter sums)FY21 $3.0M · FY22 $1.4M · FY23 $3.5M · FY24 $0 · FY25 $5.8M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $146.8M · Total debt $19.9M · Total assets $179.5M · Shareholders' equity $128.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 57.00M · Float 36.62M · 64.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 5.78M | 9.99% | 13G | May 15, 2026 |
| Orin Hirschman | 3.10M | 5.40% | 13G | Apr 28, 2026 |
| Funicular Funds, LP | 3.01M | 5.30% | 13G | Apr 6, 2026 |
| BlackRock, Inc. | 2.95M | 5.80% | 13G | Jul 17, 2025 |
| Daniel Kaufman | 2.94M | 5.16% | 13G | Mar 27, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 21, 2026 | Joseph Walter Vazzano | officer: Chief Financial Officer | −1,478 | $6.53 |
| Jul 9, 2026 | Madhav Vasanthavada | officer: Chief Commercial Officer | −12,606 | $6.96 |
| Jul 9, 2026 | Brendan M. O'Malley | officer: SVP, Chief Legal Officer | −12,050 | $6.96 |
| Jul 9, 2026 | Vishwas Seshadri | director, officer: Chief Executive Officer | −67,971 | $6.96 |
| Jul 9, 2026 | Joseph Walter Vazzano | officer: Chief Financial Officer | −24,880 | $6.96 |
Peers
- Krystal Biotech
Direct DEB wound gene-therapy rival with VYJUVEK
- Vericel
Autologous cell-therapy peer in skin replacement and burns
- Rocket Pharmaceuticals
Rare pediatric ex vivo gene-therapy peer with KRESLADI
- Sarepta Therapeutics
Scaled rare-disease gene-therapy operator with ELEVIDYS
- Vertex Pharmaceuticals
Large cell/gene therapy commercial peer with CASGEVY
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Abeona Therapeutics | $5.97 | +0.67% | $337.4M | — | — | 13.2 | +2,745.0% |
| Krystal Biotech | $351.46 | +0.05% | $10.36B | 44.0 | 41.3 | 23.5 | +24.1% |
| Vericel | $40.95 | 0.00% | $2.10B | 87.5 | 61.6 | 6.8 | +22.5% |
| Rocket Pharmaceuticals | $3.82 | −0.91% | $421.5M | — | — | — | — |
| Sarepta Therapeutics | $21.05 | +0.98% | $2.20B | — | 26.3 | 1.1 | −34.3% |
| Vertex Pharmaceuticals | $540.78 | −0.17% | $137.48B | 31.5 | 27.8 | 10.9 | +12.5% |
| Median | 44.0 | 34.6 | 8.9 | +17.5% |